Bayer markets GW Pharmaceuticals' cannabis drug; terminated
In its first commercial collaboration, GW Pharmaceuticals PLC, a company developing drugs derived from cannabis, licensed Bayer exclusive UK marketing rights to its sublingual cannabis extract spray. The candidate, in regulatory review to treat neuropathic pain and symptoms of multiple sclerosis, will be sold by prescription in the UK under the brandname Sativex.
- Includes Equity
- Includes Royalty or Profit Split Information
- Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com